ArticleBiochemistry and biophysics reports2026
Do softgel manufacturing or gastric conditions break down carrageenan into poligeenan?
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carrageenan (CGN) is a high molecular weight (typically 200-800 kDa) polysaccharide derived from red seaweed. It is used as a food additive and as a functional excipient in pharmaceutical and nutraceutical products. In softgels, CGN can offer advantages over gelatin, including pH tolerance up to 12, thermal stability during processing (70-90 °C), and resistance to cross-linking. However, under extreme conditions, such as prolonged exposure to strong acid and temperatures exceeding 100 °C, CGN may degrade into low-molecular-weight fragments (<20 kDa), known as poligeenan, which has been linked to toxicological effects. This study investigates whether conditions used in softgel manufacturing or simulated gastrointestinal digestion could cause CGN to degrade into poligeenan or similar low-molecular-weight species. Iota carrageenan from three different batches used in food, nutraceutical, and pharmaceutical products was subjected to controlled stress conditions, including high temperature and low pH. Molecular weight distributions were measured using gel permeation chromatography (GPC). Carrageenan exhibited excellent thermal stability at 95 °C and 105 °C without significant molecular weight reduction when not exposed to acid. Under gastric-simulating conditions (pH 1.2 at 37 °C), moderate hydrolysis occurred, but fragments remained above the 20 kDa threshold. In contrast, combined acid and high-temperature treatment induced substantial degradation, yielding fragments under 20 kDa. No low-molecular-weight fragments consistent with poligeenan (<20 kDa) were observed under relevant conditions, reinforcing carrageenan's safety profile for use as a functional excipient in controlled-release dosage forms and dietary supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.